Pablo Botas
Research Subjects
Pablo Botas has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Clemens Grassberger
University of Washington 4 Seattle
2 shared publications Drosoula Giantsoudi
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
2 shared publicationsHarald Paganetti
Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
2 shared publications- Harald Paganetti
Massachusetts General Hospital and Harvard Medical School
2 shared publications - Kai Wang
University of Pennsylvania
2 shared publications - Abigail Ortiz
Department of Psychiatry, Faculty of Medicine, UT Southwestern Medical Center, Dallas, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
The Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
Top Cited PapersOpen AccessThe Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- Open Access
Open-Source Artificial Intelligence System Supports Diagnosis of Mendelian Diseases in Acutely Ill Infants
Mendelian disorders are prevalent in neonatal and pediatric intensive care units and are a leading cause of morbidity and mortality in these settings. Current diagnostic pipelines that integrate phenotypic and genotypic data are expert-dependent and time-intensive. Artificial intelligence (AI) tools may help address these challenges. Dx29 is an open-source AI tool designed for use by clinicians. It analyzes the patient’s phenotype and genotype to generate a ranked differential diagnosis. We used Dx29 to retrospectively analyze 25 acutely ill infants who had been diagnosed with a Mendelian disorder, using a targeted panel of ~5000 genes. For each case, a trio (proband and both parents) file containing gene variant information was analyzed, alongside patient phenotype, which was provided to Dx29 by three approaches: (1) AI extraction from medical records, (2) AI extraction with manual review/editing, and (3) manual entry. We then identified the rank of the correct diagnosis in Dx29’s differential diagnosis. With these three approaches, Dx29 ranked the correct diagnosis in the top 10 in 92–96% of cases. These results suggest that non-expert use of Dx29’s automated phenotyping and subsequent data analysis may compare favorably to standard workflows utilized by bioinformatics experts to analyze genomic data and diagnose Mendelian diseases.
Open AccessOpen-Source Artificial Intelligence System Supports Diagnosis of Mendelian Diseases in Acutely Ill Infants
Mendelian disorders are prevalent in neonatal and pediatric intensive care units and are a leading cause of morbidity and mortality in these settings. Current diagnostic pipelines that integrate phenotypic and genotypic data are expert-dependent and time-intensive. Artificial intelligence (AI) tools may help address these challenges. Dx29 is an open-source AI tool designed for use by clinicians. It analyzes the patient’s phenotype and genotype to generate a ranked differential diagnosis. We used Dx29 to retrospectively analyze 25 acutely ill infants who had been diagnosed with a Mendelian disorder, using a targeted panel of ~5000 genes. For each case, a trio (proband and both parents) file containing gene variant information was analyzed, alongside patient phenotype, which was provided to Dx29 by three approaches: (1) AI extraction from medical records, (2) AI extraction with manual review/editing, and (3) manual entry. We then identified the rank of the correct diagnosis in Dx29’s differential diagnosis. With these three approaches, Dx29 ranked the correct diagnosis in the top 10 in 92–96% of cases. These results suggest that non-expert use of Dx29’s automated phenotyping and subsequent data analysis may compare favorably to standard workflows utilized by bioinformatics experts to analyze genomic data and diagnose Mendelian diseases.
- Top Cited Papers
- 15 November 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (22) , 22TR01
Adaptive proton therapy
Radiation therapy treatments are typically planned based on a single image set, assuming that the patient’s anatomy and its position relative to the delivery system remains constant during the course of treatment. Similarly, the prescription dose assumes constant biological dose-response over the treatment course. However, variations can and do occur on multiple time scales. For treatment sites with significant intra-fractional motion, geometric changes happen over seconds or minutes, while biological considerations change over days or weeks. At an intermediate timescale, geometric changes occur between daily treatment fractions. Adaptive radiation therapy is applied to consider changes in patient anatomy during the course of fractionated treatment delivery. While traditionally adaptation has been done off-line with replanning based on new CT images, online treatment adaptation based on on-board imaging has gained momentum in recent years due to advanced imaging techniques combined with treatment delivery systems. Adaptation is particularly important in proton therapy where small changes in patient anatomy can lead to significant dose perturbations due to the dose conformality and finite range of proton beams. This review summarizes the current state-of-the-art of on-line adaptive proton therapy and identifies areas requiring further research.
- 15 November 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (22) , 22TR01
Top Cited PapersAdaptive proton therapy
Radiation therapy treatments are typically planned based on a single image set, assuming that the patient’s anatomy and its position relative to the delivery system remains constant during the course of treatment. Similarly, the prescription dose assumes constant biological dose-response over the treatment course. However, variations can and do occur on multiple time scales. For treatment sites with significant intra-fractional motion, geometric changes happen over seconds or minutes, while biological considerations change over days or weeks. At an intermediate timescale, geometric changes occur between daily treatment fractions. Adaptive radiation therapy is applied to consider changes in patient anatomy during the course of fractionated treatment delivery. While traditionally adaptation has been done off-line with replanning based on new CT images, online treatment adaptation based on on-board imaging has gained momentum in recent years due to advanced imaging techniques combined with treatment delivery systems. Adaptation is particularly important in proton therapy where small changes in patient anatomy can lead to significant dose perturbations due to the dose conformality and finite range of proton beams. This review summarizes the current state-of-the-art of on-line adaptive proton therapy and identifies areas requiring further research.
- Open Access
- 25 May 2020
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 2 (2) , lqaa032
Phen2Gene: rapid phenotype-driven gene prioritization for rare diseases
Human Phenotype Ontology (HPO) terms are increasingly used in diagnostic settings to aid in the characterization of patient phenotypes. The HPO annotation database is updated frequently and can provide detailed phenotype knowledge on various human diseases, and many HPO terms are now mapped to candidate causal genes with binary relationships. To further improve the genetic diagnosis of rare diseases, we incorporated these HPO annotations, gene–disease databases and gene–gene databases in a probabilistic model to build a novel HPO-driven gene prioritization tool, Phen2Gene. Phen2Gene accesses a database built upon this information called the HPO2Gene Knowledgebase (H2GKB), which provides weighted and ranked gene lists for every HPO term. Phen2Gene is then able to access the H2GKB for patient-specific lists of HPO terms or PhenoPacket descriptions supported by GA4GH (http://phenopackets.org/), calculate a prioritized gene list based on a probabilistic model and output gene–disease relationships with great accuracy. Phen2Gene outperforms existing gene prioritization tools in speed and acts as a real-time phenotype-driven gene prioritization tool to aid the clinical diagnosis of rare undiagnosed diseases. In addition to a command line tool released under the MIT license (https://github.com/WGLab/Phen2Gene), we also developed a web server and web service (https://phen2gene.wglab.org/) for running the tool via web interface or RESTful API queries. Finally, we have curated a large amount of benchmarking data for phenotype-to-gene tools involving 197 patients across 76 scientific articles and 85 patients’ de-identified HPO term data from the Children’s Hospital of Philadelphia.
- 25 May 2020
- Published by Oxford University Press (OUP) in NAR Genomics and Bioinformatics
- Vol. 2 (2) , lqaa032
Open AccessPhen2Gene: rapid phenotype-driven gene prioritization for rare diseases
Human Phenotype Ontology (HPO) terms are increasingly used in diagnostic settings to aid in the characterization of patient phenotypes. The HPO annotation database is updated frequently and can provide detailed phenotype knowledge on various human diseases, and many HPO terms are now mapped to candidate causal genes with binary relationships. To further improve the genetic diagnosis of rare diseases, we incorporated these HPO annotations, gene–disease databases and gene–gene databases in a probabilistic model to build a novel HPO-driven gene prioritization tool, Phen2Gene. Phen2Gene accesses a database built upon this information called the HPO2Gene Knowledgebase (H2GKB), which provides weighted and ranked gene lists for every HPO term. Phen2Gene is then able to access the H2GKB for patient-specific lists of HPO terms or PhenoPacket descriptions supported by GA4GH (http://phenopackets.org/), calculate a prioritized gene list based on a probabilistic model and output gene–disease relationships with great accuracy. Phen2Gene outperforms existing gene prioritization tools in speed and acts as a real-time phenotype-driven gene prioritization tool to aid the clinical diagnosis of rare undiagnosed diseases. In addition to a command line tool released under the MIT license (https://github.com/WGLab/Phen2Gene), we also developed a web server and web service (https://phen2gene.wglab.org/) for running the tool via web interface or RESTful API queries. Finally, we have curated a large amount of benchmarking data for phenotype-to-gene tools involving 197 patients across 76 scientific articles and 85 patients’ de-identified HPO term data from the Children’s Hospital of Philadelphia.
- 19 December 2018
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (1) , 015004
Online adaption approaches for intensity modulated proton therapy for head and neck patients based on cone beam CTs and Monte Carlo simulations
To develop an online plan adaptation algorithm for intensity modulated proton therapy (IMPT) based on fast Monte Carlo dose calculation and cone beam CT (CBCT) imaging. A cohort of ten head and neck cancer patients with an average of six CBCT scans were studied. To adapt the treatment plan to the new patient geometry, contours were propagated to the CBCTs with a vector field (VF) calculated with deformable image registration between the CT and the CBCTs. Within the adaptive planning algorithm, beamlets were shifted following the VF at their distal falloff and raytraced in the CBCT to adjust their energies, creating a geometrically adapted plan. Four geometric adaptation modes were studied: unconstrained geometric shifts (Free), isocenter shift (Iso), a range shifter (RS), or isocenter shift and range shifter (Iso-RS). After evaluation of the geometrical adaptation, the weights of a selected subset of beamlets were automatically tuned using MC-generated influence matrices to fulfill the original plan requirements. All beamlet calculations were done with a fast Monte Carlo running on a GPU (graphics processing unit). Geometrical adaptation alone only worked with small anatomy changes. The weight-tuned adaptation worked for every fraction, with the Free and Iso modes performing similarly and being superior than the two range shifters modes. The mean V95 and V107 were 99.4 ± 0.9 and 6.4% ± 4.7% in the Free mode with weight tuning. The calculation time per fraction was ~5 min, but further task parallelization could reduce it to ~1–2 min for delivery adaptation right after patient setup. An online adaptation algorithm was developed that significantly improved the treatment quality for inter-fractional geometry changes. Clinical implementation of the algorithm would allow delivery adaptation right before treatment and thus allow planning margin reductions for IMPT.
- 19 December 2018
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 64 (1) , 015004
Online adaption approaches for intensity modulated proton therapy for head and neck patients based on cone beam CTs and Monte Carlo simulations
To develop an online plan adaptation algorithm for intensity modulated proton therapy (IMPT) based on fast Monte Carlo dose calculation and cone beam CT (CBCT) imaging. A cohort of ten head and neck cancer patients with an average of six CBCT scans were studied. To adapt the treatment plan to the new patient geometry, contours were propagated to the CBCTs with a vector field (VF) calculated with deformable image registration between the CT and the CBCTs. Within the adaptive planning algorithm, beamlets were shifted following the VF at their distal falloff and raytraced in the CBCT to adjust their energies, creating a geometrically adapted plan. Four geometric adaptation modes were studied: unconstrained geometric shifts (Free), isocenter shift (Iso), a range shifter (RS), or isocenter shift and range shifter (Iso-RS). After evaluation of the geometrical adaptation, the weights of a selected subset of beamlets were automatically tuned using MC-generated influence matrices to fulfill the original plan requirements. All beamlet calculations were done with a fast Monte Carlo running on a GPU (graphics processing unit). Geometrical adaptation alone only worked with small anatomy changes. The weight-tuned adaptation worked for every fraction, with the Free and Iso modes performing similarly and being superior than the two range shifters modes. The mean V95 and V107 were 99.4 ± 0.9 and 6.4% ± 4.7% in the Free mode with weight tuning. The calculation time per fraction was ~5 min, but further task parallelization could reduce it to ~1–2 min for delivery adaptation right after patient setup. An online adaptation algorithm was developed that significantly improved the treatment quality for inter-fractional geometry changes. Clinical implementation of the algorithm would allow delivery adaptation right before treatment and thus allow planning margin reductions for IMPT.
- Open Access
- 30 January 2018
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 63 (3) , 035023
Density overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors
The purpose of this study was to investigate internal tumor volume density overwrite strategies to minimize intensity modulated proton therapy (IMPT) plan degradation of mobile lung tumors. Four planning paradigms were compared for nine lung cancer patients. Internal gross tumor volume (IGTV) and internal clinical target volume (ICTV) structures were defined encompassing their respective volumes in every 4DCT phase. The paradigms use different planning CT (pCT) created from the average intensity projection (AIP) of the 4DCT, overwriting the density within the IGTV to account for movement. The density overwrites were: (a) constant filling with 100 HU (C100) or (b) 50 HU (C50), (c) maximum intensity projection (MIP) across phases, and (d) water equivalent path length (WEPL) consideration from beam’s-eye-view. Plans were created optimizing dose-influence matrices calculated with fast GPU Monte Carlo (MC) simulations in each pCT. Plans were evaluated with MC on the 4DCTs using a model of the beam delivery time structure. Dose accumulation was performed using deformable image registration. Interplay effect was addressed applying 10 times rescanning. Significantly less DVH metrics degradation occurred when using MIP and WEPL approaches. Target coverage ( D 99 ⩾ 70 Gy(RBE)) was fulfilled in most cases with MIP and WEPL ( D 99 W E P L = 69.2 ± 4.0 Gy (RBE)), keeping dose heterogeneity low ( D 5 − D 95 W E P L = 3.9 ± 2.0 Gy(RBE)). The mean lung dose was kept lowest by the WEPL strategy, as well as the maximum dose to organs at risk (OARs). The impact on dose levels in the heart, spinal cord and esophagus were patient specific. Overall, the WEPL strategy gives the best performance and should be preferred when using a 3D static geometry for lung cancer IMPT treatment planning. Newly available fast MC methods make it possible to handle long simulations based on 4D data sets to perform studies with high accuracy and efficiency, even prior to individual treatment planning.
- 30 January 2018
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 63 (3) , 035023
Open AccessDensity overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors
The purpose of this study was to investigate internal tumor volume density overwrite strategies to minimize intensity modulated proton therapy (IMPT) plan degradation of mobile lung tumors. Four planning paradigms were compared for nine lung cancer patients. Internal gross tumor volume (IGTV) and internal clinical target volume (ICTV) structures were defined encompassing their respective volumes in every 4DCT phase. The paradigms use different planning CT (pCT) created from the average intensity projection (AIP) of the 4DCT, overwriting the density within the IGTV to account for movement. The density overwrites were: (a) constant filling with 100 HU (C100) or (b) 50 HU (C50), (c) maximum intensity projection (MIP) across phases, and (d) water equivalent path length (WEPL) consideration from beam’s-eye-view. Plans were created optimizing dose-influence matrices calculated with fast GPU Monte Carlo (MC) simulations in each pCT. Plans were evaluated with MC on the 4DCTs using a model of the beam delivery time structure. Dose accumulation was performed using deformable image registration. Interplay effect was addressed applying 10 times rescanning. Significantly less DVH metrics degradation occurred when using MIP and WEPL approaches. Target coverage ( D 99 ⩾ 70 Gy(RBE)) was fulfilled in most cases with MIP and WEPL ( D 99 W E P L = 69.2 ± 4.0 Gy (RBE)), keeping dose heterogeneity low ( D 5 − D 95 W E P L = 3.9 ± 2.0 Gy(RBE)). The mean lung dose was kept lowest by the WEPL strategy, as well as the maximum dose to organs at risk (OARs). The impact on dose levels in the heart, spinal cord and esophagus were patient specific. Overall, the WEPL strategy gives the best performance and should be preferred when using a 3D static geometry for lung cancer IMPT treatment planning. Newly available fast MC methods make it possible to handle long simulations based on 4D data sets to perform studies with high accuracy and efficiency, even prior to individual treatment planning.
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S106-S107
Can Robust Optimization for Range Uncertainty in Proton Therapy Act as a Surrogate for Biological Optimization?
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99 (2) , S106-S107
Can Robust Optimization for Range Uncertainty in Proton Therapy Act as a Surrogate for Biological Optimization?
- 1 December 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (5) , 1097-1106
Reoptimization of Intensity Modulated Proton Therapy Plans Based on Linear Energy Transfer
- 1 December 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96 (5) , 1097-1106
Reoptimization of Intensity Modulated Proton Therapy Plans Based on Linear Energy Transfer
- 3 October 2016
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 61 (20) , 7347-7362
Recent developments and comprehensive evaluations of a GPU-based Monte Carlo package for proton therapy
Monte Carlo (MC) simulation is commonly considered as the most accurate dose calculation method for proton therapy. Aiming at achieving fast MC dose calculations for clinical applications, we have previously developed a graphics-processing unit (GPU)-based MC tool, gPMC. In this paper, we report our recent updates on gPMC in terms of its accuracy, portability, and functionality, as well as comprehensive tests on this tool. The new version, gPMC v2.0, was developed under the OpenCL environment to enable portability across different computational platforms. Physics models of nuclear interactions were refined to improve calculation accuracy. Scoring functions of gPMC were expanded to enable tallying particle fluence, dose deposited by different particle types, and dose-averaged linear energy transfer (LETd). A multiple counter approach was employed to improve efficiency by reducing the frequency of memory writing conflict at scoring. For dose calculation, accuracy improvements over gPMC v1.0 were observed in both water phantom cases and a patient case. For a prostate cancer case planned using high-energy proton beams, dose discrepancies in beam entrance and target region seen in gPMC v1.0 with respect to the gold standard tool for proton Monte Carlo simulations (TOPAS) results were substantially reduced and gamma test passing rate (1%/1 mm) was improved from 82.7%–93.1%. The average relative difference in LETd between gPMC and TOPAS was 1.7%. The average relative differences in the dose deposited by primary, secondary, and other heavier particles were within 2.3%, 0.4%, and 0.2%. Depending on source proton energy and phantom complexity, it took 8–17 s on an AMD Radeon R9 290x GPU to simulate 10 7 source protons, achieving less than 1 % average statistical uncertainty. As the beam size was reduced from 10 × 10 cm 2 to 1 × 1 cm 2 , the time on scoring was only increased by 4.8% with eight counters, in contrast to a 40% increase using only one counter. With the OpenCL environment, the portability of gPMC v2.0 was enhanced. It was successfully executed on different CPUs and GPUs and its performance on different devices varied depending on processing power and hardware structure.
- 3 October 2016
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 61 (20) , 7347-7362
Recent developments and comprehensive evaluations of a GPU-based Monte Carlo package for proton therapy
Monte Carlo (MC) simulation is commonly considered as the most accurate dose calculation method for proton therapy. Aiming at achieving fast MC dose calculations for clinical applications, we have previously developed a graphics-processing unit (GPU)-based MC tool, gPMC. In this paper, we report our recent updates on gPMC in terms of its accuracy, portability, and functionality, as well as comprehensive tests on this tool. The new version, gPMC v2.0, was developed under the OpenCL environment to enable portability across different computational platforms. Physics models of nuclear interactions were refined to improve calculation accuracy. Scoring functions of gPMC were expanded to enable tallying particle fluence, dose deposited by different particle types, and dose-averaged linear energy transfer (LETd). A multiple counter approach was employed to improve efficiency by reducing the frequency of memory writing conflict at scoring. For dose calculation, accuracy improvements over gPMC v1.0 were observed in both water phantom cases and a patient case. For a prostate cancer case planned using high-energy proton beams, dose discrepancies in beam entrance and target region seen in gPMC v1.0 with respect to the gold standard tool for proton Monte Carlo simulations (TOPAS) results were substantially reduced and gamma test passing rate (1%/1 mm) was improved from 82.7%–93.1%. The average relative difference in LETd between gPMC and TOPAS was 1.7%. The average relative differences in the dose deposited by primary, secondary, and other heavier particles were within 2.3%, 0.4%, and 0.2%. Depending on source proton energy and phantom complexity, it took 8–17 s on an AMD Radeon R9 290x GPU to simulate 10 7 source protons, achieving less than 1 % average statistical uncertainty. As the beam size was reduced from 10 × 10 cm 2 to 1 × 1 cm 2 , the time on scoring was only increased by 4.8% with eight counters, in contrast to a 40% increase using only one counter. With the OpenCL environment, the portability of gPMC v2.0 was enhanced. It was successfully executed on different CPUs and GPUs and its performance on different devices varied depending on processing power and hardware structure.